Gene · 92521
Papers3,158
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,641 to 1,660 of 3,158
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Rotavirus as an Expression Platform of Domains of the SARS-CoV-2 Spike Protein. | Vaccines (Basel) | 2021 | 34063562 | PubTator, text mining | PubMed |
| Molecular Perspectives of SARS-CoV-2: Pathology, Immune Evasion, and Therapeutic Interventions. | Mol Cells | 2021 | 34059561 | PubTator, text mining | PubMed |
| Whole gene analysis of a genotype G29P[6] human rotavirus strain identified in Central African Republic. | BMC Res Notes | 2021 | 34059133 | PubTator, text mining | PubMed |
| Identification of E484K and other novel SARS-COV-2 variants from the Kingdom of Bahrain. | Microb Pathog | 2021 | 34058304 | PubTator, text mining | PubMed |
| Anti-viral treatment for SARS-CoV-2 infection: A race against time amidst the ongoing pandemic. | Metabol Open | 2021 | 34056571 | PubTator, text mining | PubMed |
| Pathomechanisms, therapeutic targets and potent inhibitors of some beta-coronaviruses from bench-to-bedside. | Infect Genet Evol | 2021 | 34052418 | PubTator, text mining | PubMed |
| Feasibility of neighborhood and building scale wastewater-based genomic epidemiology for pathogen surveillance. | Sci Total Environ | 2021 | 34051492 | PubTator, text mining | PubMed |
| Translational shutdown and evasion of the innate immune response by SARS-CoV-2 NSP14 protein. | Proc Natl Acad Sci U S A | 2021 | 34045361 | PubTator, text mining | PubMed |
| E484K as an innovative phylogenetic event for viral evolution: Genomic analysis of the E484K spike mutation in SARS-CoV-2 lineages from Brazil. | Infect Genet Evol | 2021 | 34044192 | PubTator, text mining | PubMed |
| Identification of evolutionarily stable functional and immunogenic sites across the SARS-CoV-2 proteome and greater coronavirus family. | Bioinformatics | 2021 | 34043002 | PubTator, text mining | PubMed |
| Large-Scale Recombinant Production of the SARS-CoV-2 Proteome for High-Throughput and Structural Biology Applications. | Front Mol Biosci | 2021 | 34041264 | PubTator, text mining | PubMed |
| Transmission dynamics of SARS-CoV-2 within-host diversity in two major hospital outbreaks in South Africa. | Virus Evol | 2021 | 34035952 | PubTator, text mining | PubMed |
| Coronavirus disease 2019 (COVID-19): Biophysical and biochemical aspects of SARS-CoV-2 and general characteristics. | Prog Biophys Mol Biol | 2021 | 34033836 | PubTator, text mining | PubMed |
| Dynamic alteration in miRNA and mRNA expression profiles at different stages of chronic arsenic exposure-induced carcinogenesis in a human cell culture model of skin cancer. | Arch Toxicol | 2021 | 34032870 | PubTator, text mining | PubMed |
| SARS-CoV-2 simulations go exascale to predict dramatic spike opening and cryptic pockets across the proteome. | Nat Chem | 2021 | 34031561 | PubTator, text mining | PubMed |
| Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives. | Nat Commun | 2021 | 34031399 | PubTator, text mining | PubMed |
| Most Japanese individuals are genetically predisposed to recognize an immunogenic protein fragment shared between COVID-19 and common cold coronaviruses. | F1000Res | 2021 | 34026045 | PubTator, text mining | PubMed |
| Marine sulfated polysaccharides as potential antiviral drug candidates to treat Corona Virus disease (COVID-19). | Carbohydr Res | 2021 | 34015720 | PubTator, text mining | PubMed |
| 3DBionotes COVID-19 edition. | Bioinformatics | 2021 | 34014278 | PubTator, text mining | PubMed |
| Computational Approaches to Discover Novel Natural Compounds for SARS-CoV-2 Therapeutics. | ChemistryOpen | 2021 | 34010501 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/92521/papers?page=83